LifeVantage (LFVN) Aktievy
LifeVantage Corporation är verksamt inom identifiering, forskning, utveckling, formulering och försäljning av avancerade nutrigenomiska aktivatorer, kosttillskott, nootropics, viktkontroll, pre- och probiotika samt hud- och hårvårdsprodukter internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 3/6 |
Belöningar
Riskanalys
LFVN Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LifeVantage Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$6.24 |
| 52 veckors högsta | US$15.00 |
| 52 veckors lägsta | US$3.90 |
| Beta | 0.76 |
| 1 månads förändring | -34.18% |
| 3 månaders förändring | 50.36% |
| 1 års förändring | -48.04% |
| 3 års förändring | 39.60% |
| 5 års förändring | -13.81% |
| Förändring sedan börsintroduktionen | -74.53% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 09
LFVN: Index Removals And Weaker Margins Will Pressure Future Returns
Analysts have reduced their LifeVantage price target from $12.00 to $5.00, citing updated expectations for lower revenue growth and profit margins, along with a higher future P/E assumption. What’s in the News for LifeVantage LifeVantage was removed from multiple FTSE Russell benchmarks, including the Russell 2000 Growth, Russell 2000 Defensive, Russell 2000 Dynamic, Russell 2500, Russell 3000, Russell 3000E, Russell 3000 Growth, Russell 3000E Growth, Russell 2500 Growth, Russell Small Cap Completeness, and Russell Small Cap Completeness Growth indexes, according to index constituent change updates.
Uppdatering av berättelse • Jun 24
LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside
Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.Uppdatering av berättelse • Jun 08
LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support
Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.Recent updates
Uppdatering av berättelse • Jul 09
LFVN: Index Removals And Weaker Margins Will Pressure Future Returns
Analysts have reduced their LifeVantage price target from $12.00 to $5.00, citing updated expectations for lower revenue growth and profit margins, along with a higher future P/E assumption. What’s in the News for LifeVantage LifeVantage was removed from multiple FTSE Russell benchmarks, including the Russell 2000 Growth, Russell 2000 Defensive, Russell 2000 Dynamic, Russell 2500, Russell 3000, Russell 3000E, Russell 3000 Growth, Russell 3000E Growth, Russell 2500 Growth, Russell Small Cap Completeness, and Russell Small Cap Completeness Growth indexes, according to index constituent change updates.Uppdatering av berättelse • Jun 24
LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside
Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.Uppdatering av berättelse • Jun 08
LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support
Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.Uppdatering av berättelse • May 17
LFVN: Reset Expectations And Portugal Expansion Will Support Future Upside Potential
Analysts cut their price target on LifeVantage from $8 to $7, reflecting a lower fair value estimate, softer profit margin assumptions, and a higher future P/E, following the recent downgrade highlighted in Street research. Analyst Commentary Recent Street commentary points to a more cautious stance on LifeVantage, with the lower price target tied to reassessed earnings power and valuation assumptions following the downgrade.Uppdatering av berättelse • May 01
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.Uppdatering av berättelse • Apr 17
LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.Uppdatering av berättelse • Apr 02
LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.Uppdatering av berättelse • Mar 19
LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.Uppdatering av berättelse • Mar 05
LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.Uppdatering av berättelse • Feb 18
LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Analysartikel • Feb 06
Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...Uppdatering av berättelse • Feb 04
LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).Uppdatering av berättelse • Jan 21
LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).Uppdatering av berättelse • Jan 07
LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).Uppdatering av berättelse • Dec 22
LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.Uppdatering av berättelse • Dec 08
LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).Uppdatering av berättelse • Nov 24
LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Analysartikel • Nov 14
Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...Analysartikel • Nov 04
We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Sep 30
It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...Analysartikel • Sep 05
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...Seeking Alpha • Jul 21
The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking AlphaAnalysartikel • May 13
Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...Analysartikel • May 02
What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...Aktieägarnas avkastning
| LFVN | US Personal Products | US Marknad | |
|---|---|---|---|
| 7D | 0.3% | -1.5% | 0.7% |
| 1Y | -48.0% | -17.0% | 20.6% |
Avkastning vs industri: LFVN presterade sämre än US Personal Products branschen som gav -17 % under det senaste året.
Avkastning vs Marknaden: LFVN presterade sämre än US marknaden som gav 20.6 % under det senaste året.
Prisvolatilitet
| LFVN volatility | |
|---|---|
| LFVN Average Weekly Movement | 16.9% |
| Personal Products Industry Average Movement | 8.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: LFVN s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: LFVN s veckovolatilitet har ökat från 11% till 17% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| n/a | 235 | Michael Beindorff | www.lifevantage.com |
LifeVantage Corporation är verksamt inom identifiering, forskning, utveckling, formulering och försäljning av avancerade nutrigenomiska aktivatorer, kosttillskott, nootropics, viktkontroll, pre- och probiotika samt hud- och hårvårdsprodukter internationellt. Företaget erbjuder Protandim, ett kosttillskott; LifeVantage Omega+, ett kosttillskott som kombinerar DHA och EPA Omega-3 och Omega-7 fettsyror och vitamin D3; LifeVantage ProBio, ett kosttillskott för att stödja tarmhälsan; LifeVantage IC Bright, ett kosttillskott för att stödja ögon- och hjärnhälsan, minska trötthet och ansträngning i ögonen, stödja kognitiva funktioner och stödja normala sömnmönster; LifeVantage Daily Wellness, ett kosttillskott för att stärka immunförsvaret; LifeVantage Rise AM och Reset PM System som förser kroppen med rätt näringsämnen; LifeVantage D3+, ett kosttillskott som innehåller vitamin D3 och K2, magnesium, kalcium och andra spårmineraler för att stödja ett balanserat immunsystem, starka ben och kardiovaskulär hälsa; PhysIQ Fat Burn för att stödja viktkontroll; PhysIQ Prebiotic är ett kosttillskott som är utformat för att stödja de goda bakterierna i tarmen och ett hälsosamt mikrobiom; MindBody GLP-1 System, ett kosttillskott som kombinerar två produkter, MB Core och MB Enhance, som är utformade för att stödja viktkontroll och välbefinnande genom att aktivera GLP-1 naturligt och balansera signaler längs tarm-hjärnaxeln; Petandim for Dogs, ett tillskott för att bekämpa oxidativ stress hos hundar; och Axio, en nootropisk energidrycksmix. Företaget tillhandahåller också hudvårdsprodukter mot åldrande, såsom flytande kollagen, ansiktsrengöring, ögonkräm, fuktkräm, solskyddsmedel, perfektionerande lotioner och handkrämer samt schampon, vårdande balsam och skalpserum under varumärket TrueScience.
LifeVantage Corporation Sammanfattning av grunderna
| LFVN grundläggande statistik | |
|---|---|
| Börsvärde | US$78.85m |
| Vinst(TTM) | US$5.75m |
| Intäkter(TTM) | US$195.32m |
13.7x
P/E-förhållande0.4x
P/S-förhållandeÄr LFVN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| LFVN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$195.32m |
| Kostnad för intäkter | US$42.70m |
| Bruttovinst | US$152.62m |
| Övriga kostnader | US$146.87m |
| Intäkter | US$5.75m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.46 |
| Bruttomarginal | 78.14% |
| Nettovinstmarginal | 2.94% |
| Skuld/egenkapitalförhållande | 0% |
Hur har LFVN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
2.9%
Aktuell utdelningsavkastning39%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 09:35 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
LifeVantage Corporation bevakas av 5 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |